5bou

Publication Abstract from PubMed

The proteasome represents a validated drug target for the treatment of cancer, however, new types of inhibitors are required to tackle the development of resistant tumors. Current fluorescence-based screening methods suffer from low sensitivity and are limited to the detection of ligands with conventional binding profiles. In response to these drawbacks, a crystallographic screening procedure for the discovery of agents with a novel mode of action was utilized. The optimized workflow was applied to the screening of a focused set of compounds, resulting in the discovery of a beta1/beta2-specific sulfonamide derivative that noncovalently binds between subunits beta1 and beta2. The binding pocket displays significant differences in size and polarity between the immuno- and constitutive proteasome. The identified ligand thus provides valuable insights for the future structure-based design of subtype-specific proteasome inhibitors.

Identification of a beta1/beta2-Specific Sulfonamide Proteasome Ligand by Crystallographic Screening.,Beck P, Reboud-Ravaux M, Groll M Angew Chem Int Ed Engl. 2015 Aug 4. doi: 10.1002/anie.201505054. PMID:26242779^[1]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.